Emerging data suggests that retatrutide, a dual-action medication, may represent a considerable improvement in body reduction . This treatment combines the properties of a GLP-1 analog and a GIP analog, possibly offering a more benefit than current therapies . Patient assessments have revealed encouraging outcomes, including considerable reduction